Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Carcinoma Stories

2012-02-16 14:00:49

Paradox explored in a study reported in the American Journal of Pathology The trefoil factor 3 (TFF3) protein protects and maintains the integrity of the epithelial surface in the normal breast. New research has found that while TFF3 protein expression is higher in well-differentiated low grade tumors and therefore associated with features of a good prognosis, it has a more sinister role in breast cancer invasion and metastasis. The report is published in the March issue of the American...

2012-02-07 23:20:54

    Some early-stage breast cancers are potentially harmless, but others invade surrounding healthy tissue and become deadly.     This study has identified a small pattern of molecules that highlights important differences between early-stage breast tumors and invasive, deadly ones.     The findings might lead to a way to identify early tumors that will likely become invasive. Researchers have discovered a restricted pattern of molecules that...

2012-01-26 12:08:09

Researchers at CIC Biogune, the Cooperative Centre for Research into Biosciences and led by Dr. Maria Luz Martinez Chantar, have found a strong relationship between high levels of Hu antigen R (HuR) protein and the malignancy of Hepatocellular Carcinoma, through a novel molecular process in the investigation of this pathology and known as neddylation. The project provides new opportunities for making advances in the quest for personalized therapeutic applications in the treatment for...

2012-01-19 10:16:46

Drug used to treat melanoma with 1 mutation sets off a cascade that results in a different type of skin cancer in cells with another mutation Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf®) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and...

2012-01-18 00:08:25

Some skin cancers, in particular basal cell carcinoma, can be successfully treated with a prescription cream containing the compound imiquimod. The antitumor effect of imiquimod is multifactorial. One of the more complex aspects of imiquimod's antitumor effects is its ability to modify the immune response. A team of researchers led by Maria Sibilia, at the Medical University of Vienna, Austria, has now identified a new way in which imiquimod modifies the immune system to clear tumors in a...

2012-01-10 08:00:00

SAN DIEGO, Jan. 10, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in combination with docetaxel in advanced solid tumors with emphasis on prostate cancer patients. Patients with advanced solid tumors, including castration resistant prostate cancer, who are candidates for docetaxel, will be treated with a standard...

2012-01-09 19:51:39

Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan. 8-11, 2012. Data also demonstrated that the EGFR and KRAS genes, which are mutually exclusive, can be used to define clinically relevant molecular subsets of lung adenocarcinoma and can define tumor clonality. "The information on genetic...

2011-11-22 08:26:20

(Ivanhoe Newswire) — Papillary carcinoma is the most common type of thyroid cancer, and about one fourth of these carcinomas have mutations in the BRAF gene. These mutations are most common in high-grade carcinomas, in particular, the ones that resist standard treatments. According to researchers at Memorial Sloan-Kettering Cancer Center, New York, exploiting the expression of BRAF by the resistant cancers could be a therapeutic advantage. Despite the prevalence of BRAF mutations in...

2011-11-21 23:09:28

Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly those that are refractory to standard treatment, which is radioactive iodine (RAI). A team of researchers led by James Fagin, at Memorial Sloan-Kettering Cancer Center, New York, has now identified a way to potentially exploit the expression of BRAF by such cancers...

2011-11-17 10:20:06

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease. Mark Rubin, M.D., professor of pathology and laboratory medicine at Weill Cornell Medical College, said although fewer than 2 percent of men with prostate cancer present with neuroendocrine prostate cancer, the more common prostate adenocarcinoma can also evolve into...